Results
|
|
1.
|
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. MedStar authors:
Year: 2017
Citation: - Journal of Thrombosis & Thrombolysis. 43(2):166-171, 2017 Feb
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Validation Studies
All authors: - Brar G, Harnicar S, Laube E, Mantha S, Miao Y, Parameswaran R, Samedy P, Sarasohn DM, Soff GA, Stefanik S, Wills J
|
|
|
2.
|
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. MedStar authors:
Citation: - Journal of Thrombosis & Thrombolysis. 36(4):375-83, 2013 Nov.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, N.I.H., Intramural
All authors: - Adams SD, Barsness GW, Harrington RA, Hasselblad V, Heitner JF, Kelly F, Kim RJ, Lakatta EG, Melton LG, Najjar SS, Patel MR, Povsic TJ, Prather K, Raman SV, Rao SV, Zavodni KL, Zhou J
|
|
|
3.
|
Albumin and bleed risk in rivaroxaban treated patients. MedStar authors:
Year: 2020
Citation: - Journal of Thrombosis & Thrombolysis. 50(4):1004-1011, 2020 Nov.
Institution: - MedStar Union Memorial Hospital
Medline publication type:
All authors: - Chen L, Cheruvil C, Hassan A, Holsen MR, Rossi M, Wilcox N, Wojakowski E
|
